DHR · Earnings call · 2026Q3T · Full report

China Healthcare Policy Changes

DANAHER CORP /DE/ · 2026-10-21 · Importance 25 · Surprise 32

Management said Diagnostics continued to move beyond the most significant impacts of China’s healthcare policy changes, and that easing policy-related headwinds supported confidence in Beckman Coulter Diagnostics’ growth trajectory. China core revenue grew high single digits in the quarter, with growth across all three segments. Management did not quantify the policy-related impact or provide a specific future policy timeline.